483 related articles for article (PubMed ID: 25128477)
1. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
Flamm RK; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
[TBL] [Abstract][Full Text] [Related]
2. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
Sader HS; Huband MD; Duncan LR; Flamm RK
Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
10.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
11. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
12. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
Flamm RK; Stone GG; Sader HS; Jones RN; Nichols WW
J Chemother; 2014 Dec; 26(6):333-8. PubMed ID: 24125508
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):449-56. PubMed ID: 24529941
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
15. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Pitart C; Marco F; Keating TA; Nichols WW; Vila J
Antimicrob Agents Chemother; 2015; 59(6):3059-65. PubMed ID: 25753646
[TBL] [Abstract][Full Text] [Related]
16. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
Sader HS; Castanheira M; Jones RN; Flamm RK
Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
[TBL] [Abstract][Full Text] [Related]
19.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]